Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JUSTICE's SELACRYN CASE FINAL ACT HINGES ON POTENTIAL PENALTIES FOR INDIVIDUALS; PROSECUTION, NEW NDA REGS UNDERSCORE SERIOUSNESS OF NEW REPORTING RULES

Executive Summary

The major remaining issue in the Justice Dept. case against SmithKline Beckman over Selacryn (ticrynafen) involves potential penalties for three employee defendants: U.S. VP-Medical Director Philip Tannenbaum, MD; U.S. Group Director-Medical Affairs Ralph Myerson, MD; and former Associate Medical Director Thomas Selby, MD, (now with Wyeth). On Dec. 12, the three individuals pleaded no contest to 14 counts alleging violation of FDA adverse drug reaction reporting requirements. In exchange for the no contest pleas, Justice dropped another 20 counts of misbranding. The corporation pleaded guilty to all 34 counts. All of the charges are misdemeanors and carry a maximum penalty of $1,000 per count. However, the individuals also face possible prison terms of one year per count. At the court appearance Dec. 12, Judge Edward Cahn told the three employees that he will allow them to change their pleas to innocent, should he consider imposing prison terms. The Justice Dept. indicated at the hearing that it would seek to dismiss charges against SK&F VP-Medical Director Thomas Davis, MD. The govt.'s allegations against Davis involve the 20 misbranding charges. SmithKline Faces About One Dozen Outstanding Private Liability Suits: Punitive Awards Could Be Outside Insurance The Justice Dept. filed the case last June, after a three-year investigation. Seven of the allegations relating to adverse drug reporting related to failure to include in three-month post-marketing reports adverse reaction information received from Anphar, the French firm from which SmithKline licensed Selacryn. The other seven charges involved failure to report to FDA within 15 days "unexpected" side effects. The misbranding charges were based on Justice's allegation that the drug's labeling did not reflect all of the adverse reactions reported to the company ("The Pink Sheet" June 18, p. 12). By coincidence, the Allentown, Pa. court hearing occurred two days after HHS Secty. Heckler announced signing the new NDA regulations, which contain the revised rules for adverse drug reaction reporting. In conjunction with Justice's successful prosecution of the reporting counts of the Selacryn case, the new regs mark the increased reporting pressure on the drug industry. A similar strengthening of reporting requirements has recently been put into regulation for medical devices. The SmithKline case should have the same warning effect for companies in that industry. Regarding Selacryn-related private claims, the firm reported in its 1983 10-k annual report that, as of March 21, 1984, the firm faced 20 "outstanding lawsuits which were brought claiming damages for adverse effects (mostly liver related) from Selacryn. . . ." As of that time, the firm also was aware of 10 "additional claims pending relative to Selacryn, some of which may result in lawsuits. When Justice filed the criminal information in the Selacryn case in June, SmithKline reported that the number of outstanding suits had dropped to 11. The firm said as of Dec. 14, there were 13 outstanding suits. Noting the difference between standard liability coverage and punitive awards, SmithKline stated in its 10-k annual report that it "believes that its insurance and reserves are sufficient to cover these and other outstanding product liability suits, except for assessment of punitive damages in jurisdictions where insurance payments for punitive damages are against public policy.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel